Data Insights

S-95024 by Les Laboratoires Servier for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval

S-95024 is under clinical development by Les Laboratoires Servier and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...

Likelihood of Approval and Phase Transition Success Rate Model - S-95024 in Bile Duct Cancer (Cholangiocarcinoma)

Data Insights

S-95035 by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval

S-95035 is under clinical development by Les Laboratoires Servier and currently in Phase I for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - S-95035 in Solid Tumor

Data Insights

S-95024 by Les Laboratoires Servier for Cervical Cancer: Likelihood of Approval

S-95024 is under clinical development by Les Laboratoires Servier and currently in Phase II for Cervical Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - S-95024 in Cervical Cancer

Data Insights

Ivosidenib by Les Laboratoires Servier for Solid Tumor: Likelihood of Approval

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase II for Solid Tumor. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Solid Tumor

Data Insights

S-095029 by Les Laboratoires Servier for Gastric Cancer: Likelihood of Approval

S-095029 is under clinical development by Les Laboratoires Servier and currently in Phase II for Gastric Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - S-095029 in Gastric Cancer

Data Insights

Ivosidenib by Les Laboratoires Servier for Low-Grade Glioma: Likelihood of Approval

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase I for Low-Grade Glioma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Low-Grade Glioma

Data Insights

Ivosidenib by Les Laboratoires Servier for Chondrosarcoma: Likelihood of Approval

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase III for Chondrosarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Chondrosarcoma

Data Insights

S-64315 by Les Laboratoires Servier for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

S-64315 is under clinical development by Les Laboratoires Servier and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...

Likelihood of Approval and Phase Transition Success Rate Model - S-64315 in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)

Data Insights

Ivosidenib by Les Laboratoires Servier for Low-Grade Glioma: Likelihood of Approval

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase I for Low-Grade Glioma. According to GlobalData,...

Data Insights

Ivosidenib by Les Laboratoires Servier for Chondrosarcoma: Likelihood of Approval

Ivosidenib is under clinical development by Les Laboratoires Servier and currently in Phase III for Chondrosarcoma. According to GlobalData, Phase...

Data Insights

AUR-108 by Les Laboratoires Servier for Leukemia: Likelihood of Approval

AUR-108 is under clinical development by Les Laboratoires Servier and currently in Phase I for Leukemia. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - AUR-108 in Leukemia

Data Insights

S-65487 by Les Laboratoires Servier for Marginal Zone B-cell Lymphoma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Marginal Zone B-cell Lymphoma. According...

Data Insights

S-65487 by Les Laboratoires Servier for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...

Data Insights

S-65487 by Les Laboratoires Servier for Refractory Acute Myeloid Leukemia: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Refractory Acute Myeloid Leukemia. According...

Data Insights

S-65487 by Les Laboratoires Servier for Refractory Multiple Myeloma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Refractory Multiple Myeloma. According to...

Data Insights

S-65487 by Les Laboratoires Servier for Relapsed Multiple Myeloma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Relapsed Multiple Myeloma. According to...

Data Insights

S-65487 by Les Laboratoires Servier for Follicular Lymphoma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Follicular Lymphoma. According to GlobalData,...

Data Insights

S-65487 by Les Laboratoires Servier for Mantle Cell Lymphoma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Mantle Cell Lymphoma. According to...

Data Insights

S-65487 by Les Laboratoires Servier for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase I for Diffuse Large B-Cell Lymphoma. According...

Data Insights

S-65487 by Les Laboratoires Servier for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval

S-65487 is under clinical development by Les Laboratoires Servier and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute...